DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Positive impactResults

Rossari Biotech Q1 Results: Revenue jumps 28% YoY to Rs 697.2 crore, net profit up 4%

Business Upturn 10 hrs ago·18 Jul 2026, 11:22 am

This update concerns Rossari Biotech. Read the full report at the source below.

Stocks in this story

Rossari Biotech₹531.45▲ 0.00%

Key takeaways

Concerns Rossari Biotech (ROSSARI).
Category: Results.
AI reads the tone as positive (potentially bullish) for the stock.

Why it matters

A routine update for Rossari Biotech. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Business Upturn.